TW
EN

About UBIP
Technology Platform
RD & Products
Quality
CMO/CDMO Services
- Tailored Solutions
- Facility & Capacity
News
- Press Release
- Media Coverage
Contact us

Search

About UBIP

Company Overview

Milestone
- 2024
  - Nov 8
  - Oct 18
  - Oct 12
  - Sep 20
  - May 09
  - May 02
- 2023
  - Dec 15
  - Dec 05
  - Oct 31
  - Oct 25
  - Spe 14
  - Spe 4
  - July 24
  - March 10
  - February 7
- 2022
  - Nov 28
  - Nov 17
  - Jan 20
- 2021
  - Nov 22
  - Oct 5
  - Jun 23
  - Jun 11
- 2020
  - Sep 22
  - May 28
  - Apr 28
  - Apr 14
  - Feb 17
- 2019
  - Oct 24
  - Sep 26
  - Aug 13
  - Jun 10
  - Mar 13
  - Mar 6
  - Mar 4
  - Jan 18
  - Jan 16
- 2018
  - Dec 4
  - Oct 3
  - May 17
  - May 11
  - Mar 3
- 2017
  - Dec 7
- 2016
  - Dec 14
  - Nov 29
  - Oct 27
  - Aug 15
  - Jul 25
  - Jul 11
  - Feb 18
  - Jan 22
  - Jan 21
- 2015
  - Dec 30
  - Dec 25
  - Dec 22
  - Nov 17
  - Oct 28
  - Jul 28
  - Jun 23
  - May 28
  - May 8
  - Apr 30
  - Jan 27
  - Jan 23
- 2014
  - Jul 31

Management Team
- Chairman of the Board & CEO
- Vice General Manager

Home
About UBIP
Milestone
2014

2014

Jul 31

UBIA split its monoclonal antibody drug business and chemical pharmaceutical business to establish UBIP.

UBI Pharma Inc.

TEL +886-3-5977676
FAX +886-3-5981173
Address No.45, Guangfu N. Rd., Hukou Township, Hsinchu County 303036, Taiwan (R.O.C.)

Adverse Reaction Contact
24 hour phone +886-800-035-511
email pharmacovigilance@ubi-pharma.com

© 2026 UBI Pharma Inc. All rights reserved. Designed By Winho